# Test Results: fundamentals/chain-of-thought.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-23.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** fundamentals/chain-of-thought.md
- **Model:** nemotron-3-super-120b
- **Model ID (pinned):** Nemotron-3-Super-120B-A12B-NVFP4
- **Endpoint:** https://copilot-dev.cqls.oregonstate.edu/llm/nemotron3-super-120b-nvfp4/v1
- **Date:** 2026-06-23
- **Tester:** cross-model-harness
- **Assembly strategy:** concat
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
```
{TASK_DESCRIPTION}

Think through this step by step:
1. First, identify {RELEVANT_FACTORS}
2. Then, consider {KEY_CONSIDERATIONS}
3. Finally, {REACH_CONCLUSION}

Show your reasoning at each step before providing your final answer.
```

### Structured Version
```
{CONTEXT}

{TASK_SPECIFICATION}

Work through this systematically:

**Step 1 - {FIRST_PHASE}:**
[Explain what to analyze first]

**Step 2 - {SECOND_PHASE}:**
[Explain what to consider next]

**Step 3 - {THIRD_PHASE}:**
[Explain how to synthesize]

**Final recommendation:**
[Specify what the conclusion should include]

Show your reasoning explicitly at each step.

I need to select a statistical approach for analyzing my microbiome data. Here's my study:

- 20 mice, 10 per treatment group (probiotic vs. placebo)
- Fecal samples collected at 3 time points (days 0, 14, 28)
- Outcome: relative abundances of bacterial taxa (compositional data)
- Question: Does probiotic treatment affect community composition over time?
- Additional context: Some mice were co-housed (2-3 per cage), creating potential cage effects

Think through this step by step:

**Step 1 - Data structure:**
What are the key features of my data that affect analysis choice? Consider the experimental design, the nature of the outcome variable, and any dependencies in the data.

**Step 2 - Candidate approaches:**
What statistical approaches could address my question? For each, briefly note what it assumes and what it tests.

**Step 3 - Assumption evaluation:**
For each candidate approach, which assumptions might be problematic for my specific data structure?

**Step 4 - Practical considerations:**
What practical factors (software availability, interpretability, field conventions) should influence the choice?

**Step 5 - Recommendation:**
Based on the above, what approach or approaches would you suggest I discuss with a statistician? What specific questions should I ask them?

Show your reasoning explicitly at each step.
```

## Model Output
```


**Step 1 – Data structure:**  
*What are the key features of my data that affect analysis choice?*  

| Feature | Why it matters for the statistical method |
|---------|-------------------------------------------|
| **Sample size & replication** – 20 mice total (10 per treatment) with 3 repeated measures per mouse (days 0, 14, 28). | Gives a longitudinal/repeated‑measures design; we must account for within‑mouse correlation over time. |
| **Treatment factor** – Probiotic vs. placebo (between‑subjects). | Primary fixed effect of interest; we need to test whether the trajectory differs between groups. |
| **Time factor** – Three discrete time points (baseline, mid, end). | Allows testing of main effect of time, treatment × time interaction, and possibly non‑linear trends. |
| **Outcome** – Relative abundances of bacterial taxa (compositional data). | Data lie in a simplex (sum to 1 or 100 %); raw proportions violate assumptions of normality and constant variance. Transformations or models that respect compositionality are required. |
| **Cage effect** – Mice co‑housed (2‑3 per cage) → potential shared environment/intra‑cage correlation. | Introduces an additional random effect (cage) that can induce correlation among mice beyond the repeated‑measure structure. |
| **Sparsity / zero‑inflation** – Many taxa may be absent in some samples. | Methods should handle zeros (e.g., via pseudocounts, zero‑inflated models, or distance‑based approaches). |
| **Multiple testing** – If we look at many taxa individually, we need to control false discovery rate. | Influences choice between univariate taxon‑wise tests vs. multivariate community‑level methods. |

**Take‑away:** The analysis must (1) handle repeated measures, (2) incorporate a possible cage random effect, (3) respect the compositional nature of the data, and (4) allow testing of a treatment × time interaction on overall community composition (or on selected taxa).

---

**Step 2 – Candidate approaches:**  
*What statistical approaches could address my question? For each, briefly note what it assumes and what it tests.*

| Approach | Core idea / what it tests | Key assumptions |
|----------|--------------------------|-----------------|
| **Linear mixed‑effects model (LMM) on transformed abundances** (e.g., arcsine‑sqrt, log‑ratio, or centered log‑ratio (CLR) transformed taxa) | Tests fixed effects of treatment, time, and their interaction on each taxon (or on a summary like PC1) while modeling mouse (and optionally cage) as random intercepts. | Approx. normality of transformed residuals; homoscedasticity; independence conditional on random effects; correct specification of covariance structure. |
| **Generalized linear mixed model (GLMM) with Dirichlet‑multinomial or multinomial likelihood** | Models the count composition directly (raw read counts) as arising from a Dirichlet‑multinomial distribution; tests treatment, time, interaction via fixed effects on the mean proportions. | Counts follow Dirichlet‑multinomial; overdispersion captured by Dirichlet parameter; random effects (mouse, cage) enter via log‑link on means. |
| **Distance‑based redundancy analysis (db‑RDA) / PERMANOVA (adonis2) with strata** | Uses a dissimilarity matrix (e.g., Bray‑Curtis, weighted UniFrac) to test whether centroids of groups differ; can include treatment, time, and their interaction as predictors; strata argument can account for repeated measures (mouse) and/or cage. | Exchangeability under permutations; appropriate distance metric; homogeneity of dispersions (checked via PERMDISP). |
| **Linear mixed‑effects model on principal coordinates (PCoA) axes** | Reduces compositional data to a few orthogonal axes (e.g., via CLR → PCA) and then fits LMMs on each axis to test treatment, time, interaction. | Same as LMM; assumes axes capture sufficient variation; linearity in PC space. |
| **Multivariate mixed‑effects models (e.g., MCMCglmm, brms) on CLR‑transformed taxa** | Jointly models multiple taxa (or all taxa) with a multivariate normal likelihood after CLR transformation, allowing random effects for mouse and cage. | Multivariate normality of CLR‑transformed data; proper priors if Bayesian; sufficient sample size relative to number of taxa. |
| **Zero‑inflated Gaussian or beta mixed models** (e.g., glmmTMB with family = beta_family or zi) | Models proportions directly (0‑1) with a beta distribution, accommodating excess zeros via a zero‑inflation component; includes random effects for mouse and cage. | Beta distribution for non‑zero proportions; zero‑inflation process correctly specified; independence conditional on random effects. |
| **Longitudinal differential abundance methods** (e.g., **Songbird**, **LDM**, **MaAsLin2** with time as a covariate) | Fit taxon‑wise models (often linear or negative binomial) with fixed effects for treatment, time, interaction, and random effects for subject; correct for multiple testing. | Depends on underlying model (e.g., negative binomial for counts, Gaussian for transformed data); assumes appropriate distribution and random‑effects structure. |
| **Bayesian hierarchical Dirichlet‑multinomial model** (e.g., using **Stan** or **brms**) | Full probabilistic model of counts with Dirichlet‑multinomial likelihood, hierarchical priors on treatment/time effects, and random effects for mouse/cage. | Correct likelihood; prior choices; convergence of MCMC. |

---

**Step 3 – Assumption evaluation:**  
*For each candidate approach, which assumptions might be problematic for my specific data structure?*

| Approach | Potential problematic assumptions in this study |
|----------|---------------------------------------------------|
| **LMM on transformed abundances** | - Choosing a transformation that adequately normalizes compositional data is non‑trivial; arcsine‑sqrt works poorly for high sparsity.<br>- CLR transformation requires a pseudocount for zeros, which can bias low‑abundance taxa.<br>- With only 10 mice per group, estimating random‑effects variance (mouse, cage) may be unstable.<br>- Homoscedasticity may still be violated after transformation. |
| **GLMM (Dirichlet‑multinomial)** | - Dirichlet‑multinomial assumes that overdispersion is shared across taxa; if overdispersion varies markedly by taxon, fit may be poor.<br>- Implementation complexity; need software that supports random effects (e.g., **glmmTMB**, **brms**).<br>- With only 20 subjects, estimating many taxon‑specific overdispersion parameters can be challenging. |
| **Distance‑based PERMANOVA (adonis2)** | - PERMANOVA tests differences in centroids; it can be confounded by heterogeneity of dispersion (different variances among groups). Must check PERMDISP.<br>- The “strata” argument can handle repeated measures (mouse) but adding a second nesting level (cage) is trickier; may need to permute within cages or use a restricted permutation scheme.<br>- Does not directly give effect sizes for individual taxa; interpretation is at community level. |
| **LMM on PCoA axes** | - Reducing to a few PCs may discard biologically relevant variation, especially if treatment effect is subtle and spread across many taxa.<br>- Linear relationships in PC space may not hold; axes are not guaranteed to be independent after transformation. |
| **Multivariate mixed‑effects (MCMCglmm/brms)** | - Requires specifying a covariance matrix for the multivariate response; with many taxa (>~10) this becomes high‑dimensional and may need strong priors or dimension reduction.<br>- Computationally intensive; convergence can be problematic with limited sample size.<br>- CLR transformation still needed to avoid simplex constraints. |
| **Zero‑inflated beta mixed models** | - Beta distribution assumes continuous values strictly between 0 and 1; zeros must be modeled separately, increasing model complexity.<br>- Estimating both zero‑inflation and beta parameters with only 10 replicates per group may lead to identifiability issues.<br>- Software support for crossed random effects (mouse + cage) is limited (though glmmTMB can handle it). |
| **Longitudinal differential abundance (MaAsLin2, Songbird, LDM)** | - These methods often treat each taxon independently; they may ignore correlation among taxa, potentially inflating false positives.<br>- Some (e.g., Songbird) use multinomial regression and assume independence of samples; incorporating random effects for mouse/cage is not straightforward.<br>- LDM can include random effects but is designed for count data; may need appropriate normalization (e.g., CSS, TSS). |
| **Bayesian hierarchical Dirichlet‑multinomial** | - Fully Bayesian approach is flexible but requires careful prior specification; with small N, priors can heavily influence results.<br>- MCMC diagnostics may be challenging; need sufficient iterations and convergence checks.<br>- Computationally heavy if many taxa are included. |

**Overall assessment:**  
- The **repeated‑measure nature** and **potential cage effect** push us toward mixed‑effects formulations (random intercepts for mouse, possibly cage).  
- The **compositional, sparse, count‑based nature** of microbiome data favors models that work on raw counts or appropriate transformations (CLR, Dirichlet‑multinomial, beta, or zero‑inflated beta).  
- Because the primary scientific question is about **treatment × time interaction on overall community composition**, a **distance‑based PERMANOVA** with proper stratification is a quick, interpretable first step, *provided* we verify dispersion homogeneity.  
- For **taxon‑level inference** (e.g., which specific taxa drive any community shift), a **GLMM with Dirichlet‑multinomial likelihood** or a **zero‑inflated beta mixed model** (if we prefer to model proportions) is more principled than standard LMM on raw proportions.  
- If we are comfortable with a **dimension‑reduction + LMM** approach (e.g., CLR → PCA → LMM on first few PCs), we gain simplicity but risk losing subtle signals.

---

**Step 4 – Practical considerations:**  
*What practical factors (software availability, interpretability, field conventions) should influence the choice?*

| Factor | Relevance to our study |
|--------|------------------------|
| **Software familiarity & accessibility** | Most labs have R with packages **lme4**, **glmmTMB**, **phyloseq**, **vegan**, **MCMCglmm**, **brms**, **MaAsLin2**. If the analyst is less comfortable with Bayesian Stan models, frequentist GLMMs may be preferable. |
| **Interpretability for biologists** | PERMANOVA results (R², p‑value) are easy to communicate: “Treatment explains X% of variation in community composition over time.” LMM coefficients on transformed taxa are harder to explain to a non‑statistical audience. |
| **Handling of zeros & sparsity** | glmmTMB and brms support zero‑inflated beta and Dirichlet‑multinomial families directly; lme4 does not. If many taxa are zero‑inflated, these packages are advantageous. |
| **Ability to model crossed random effects (mouse + cage)** | glmmTMB and brms allow specifying `(1|mouse) + (1|cage)` easily. lme4 can also do this but may struggle with variance estimation given low numbers of cages. |
| **Multiple‑testing correction** | If we go taxon‑wise, we need FDR control (Benjamini‑Hochberg). Packages like **MaAsLin2** automate this; with LMMs we’d need to extract p‑values and adjust manually. |
| **Field conventions** | Many microbiome longitudinal papers use **PERMANOVA** (adonis) for overall community tests and **DESeq2/ANCOM‑BC/MAASLIN2** for differential abundance. Mixed‑effects models are gaining traction but are still less common; citing recent methodological papers (e.g., Morton et al. 2019; Weiss et al. 2021) can justify the approach. |
| **Computational time** | With 20 mice × 3 time points = 60 samples, even a fairly complex Bayesian model will run quickly (< few hours). Simpler LMM/PERMANOVA will be instantaneous. |
| **Availability of tutorials / vignettes** | phyloseq + vegan has extensive PERMANOVA tutorials; glmmTMB has vignettes for zero‑inflated beta; brms has examples for Dirichlet‑multinomial. Choosing a method with good documentation reduces implementation risk. |

---

**Step 5 – Recommendation:**  
*Based on the above, what approach or approaches would you suggest I discuss with a statistician? What specific questions should I ask them?*

### Recommended primary strategy
1. **Community‑level test:**  
   - **Distance‑based PERMANOVA (adonis2)** on a phylogenetically informed distance (e.g., weighted UniFrac) or Bray‑Curtis after CLR transformation.  
   - Use `strata = mouseID` to account for repeated measures; if cage effects are substantial, consider a **restricted permutation scheme** that permutes within cages (e.g., `permute = how(within = Within(type = "free"), plots = Plots(strata = cageID))`).  
   - Check homogeneity of dispersion with `betadisper` (PERMDISP).  

   *Why:* Gives an immediate, interpretable answer to “Does probiotic treatment affect community composition over time?” and is standard in the microbiome literature.

2. **Taxon‑level follow‑up (if PERMANOVA is significant):**  
   - Fit a **zero‑inflated beta mixed model** (or Dirichlet‑multinomial GLMM) for each taxon of interest using **glmmTMB**:  
     ```R
     glmmTMB(cbind(count, total-count) ~ treatment * time + 
               (1|mouseID) + (1|cageID), 
               family = betalink(), zi = ~1)   # zero‑inflated beta
     ```  
   - Alternatively, fit a **Dirichlet‑multinomial GLMM** via **brms**:  
     ```R
     brm(bf(counts | trials(total) ~ treatment * time + (1|mouseID) + (1|cageID)),
         family = dirichlet_multinomial(),
         data = ...)
     ```  
   - Apply **Benjamini‑Hochberg FDR** correction across taxa.  

   *Why:* These models respect the compositional nature, handle excess zeros, and allow random effects for both mouse and cage, giving effect size estimates (e.g., log‑odds ratios) for the treatment × time interaction.

### Secondary / complementary options
- **CLR‑transformed PCA + LMM on the first 2–3 PCs** (using `lme4` or `nlme`) as a quick sanity check; report variance explained by each PC and the significance of fixed effects.  
- **MaAsLin2** with `fixed effects = treatment, time, treatment:time` and `random effects = mouseID` (if the version supports it) as a user‑friendly alternative for taxon‑wise testing.

### Questions to pose to a statistician
1. **Random‑effects structure:**  
   - “Given only 10 mice per group and 2‑3 mice per cage, is it feasible to estimate separate variance components for mouse and cage, or should we nest cage within mouse (or treat cage as a fixed effect)?”  
2. **Distribution choice:**  
   - “Which likelihood (Dirichlet‑multinomial vs. zero‑inflated beta vs. Gaussian on CLR‑transformed data) best matches the observed mean‑variance relationship and zero‑inflation in our data?”  
3. **Model checking:**  
   - “What diagnostics (residual plots, posterior predictive checks, dispersion tests) should we run to verify model assumptions?”  
4. **Multiple testing:**  
   - “If we pursue taxon‑wise models, what FDR procedure do you recommend, and should we consider hierarchical testing (e.g., test phylum → family → genus)?”  
5. **Software & convergence:**  
   - “Are there known convergence issues with glmmTMB’s zero‑inflated beta or brms’ Dirichlet‑multinomial for this sample size, and what reparameterizations or priors might help?”  
6. **Power / sample‑size considerations:**  
   - “With our current design, what is the detectable effect size for a treatment × time interaction under each model, and would adding more time points or mice improve power substantially?”  
7. **Interpretation of effect sizes:**  
   - “How should we translate the model coefficients (e.g., log‑odds, CLR differences) into biologically meaningful statements about taxa abundance changes?”  

### Summary to convey to the statistician
> “We have a longitudinal mouse microbiome study (20 mice, 2 treatments, 3 time points) with potential cage effects and compositional, sparse count data. We first want to test whether the overall community composition differs by treatment over time, and second, to identify which taxa drive any observed pattern. We are considering PERMANOVA for the community test and zero‑inflated beta or Dirichlet‑multinomial mixed models for taxon‑level analysis, but we would like guidance on the appropriate random‑effects structure, distribution choice, model checking, and multiple‑testing correction given our modest sample size.”

Following this roadmap will give you a statistically rigorous, interpretable analysis that respects both the experimental design and the peculiarities of microbiome data. Good luck with your project!
```

## Overall Assessment
- **Recommendation:** Cannot judge from output alone
- **Notes:**
## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
